Home Categories Biochemical Engineering Dolutegravir (GSK1349572)
A3316112

Dolutegravir (GSK1349572) , ≥99% , 1051375-16-6

CAS NO.:1051375-16-6

Empirical Formula: C20H19F2N3O5

Molecular Weight: 419.38

MDL number: MFCD20488027

Pack Size Price Stock Quantity
5MG RMB446.40 In Stock
10MG RMB703.20 In Stock
50MG RMB2194.40 In Stock
others     Enquire
Update time: 2022-07-08

PRODUCT Properties

Melting point: 187-189°C
Boiling point: 669.0±55.0 °C(Predicted)
Density  1.53
storage temp.  Refrigerator
solubility  DMSO (Slightly, Heated, Sonicated), Methanol (Slightly, Heated, Sonicated)
pka 4.50±1.00(Predicted)
form  Solid
color  White to Pale Beige

Description and Uses

In August 2013, the US FDA approved dolutegravir (also referred to as S/GSK1349572) for the treatment of HIV-1 infection in adults and children ages 12 years and older in combination with other antiretroviral drugs. Dolutegravir was approved in Canada in November 2013. HIV/AIDS remains a global epidemic with 35 million people infected, including 2.3 million new infections as of 2012. Dolutegravir joins raltegravir and elvitegravir (this chapter of ARMC) as the latest of three FDA-approved HIV integrase strand transfer inhibitors (INSTIs). Dolutegravir was discovered by rational design from a literature diketo acid HIV integrase inhibitor utilizing X-ray coordinates to predict ideal bond angles between the diketone and distal benzyl group. In dolutegravir, the monocyclic component of the reported inhibitor was replaced with the tricyclic carbamoyl pyridone moiety. The researchers postulated that the appropriate arrangement of three oxygens would permit chelation with two magnesium ions in the binding site thus affording improved potency. Ultimately, this arrangement along with further modifications afforded dolutegravir, a potent inhibitor of HIV integrase (IC50=1.7 nM).

Dolutegravir is a second generation HIV-1 integrase strand transfer inhibitor. Dolutegravir is currently in Phase III clinical trials for the treatment of HIV infection. Dolutegravir has been shown to potently inhibit HIV replication in cells such as peripheral blood mononuclear cells (PBMCs), MT-4 cells and CIP4 cells infected with a self-inactivating PHIV lentiviral vector.

Safety

Symbol(GHS) 
GHS07
Signal word  Warning
Hazard statements  H302-H315-H319-H335
Precautionary statements  P261-P305+P351+P338
Hazardous Substances Data 1051375-16-6(Hazardous Substances Data)

RELATED PRODUCTS